Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo de estudio
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Fundam Clin Pharmacol ; 25(3): 323-32, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-20584202

RESUMEN

n-3 polyunsaturated fatty acids (omega-3) supplementation is associated with reduced cardiovascular mortality and post-infarction death. However, the impact of omega-3 supplementation in congestive heart failure (CHF) is still unknown. This study assesses the effects of omega-3 supplementation on left ventricular (LV) function and remodelling. We assessed, in rats with CHF induced by left coronary ligation, the effects of a 1-week and a 12-week supplementation with omega-3 (450 mg/kg per day) on LV hemodynamics, function and structure. Chronic omega-3 reduces total peripheral resistance due to an increase in cardiac output without modification of arterial pressure. Only chronic omega-3 reduces LV end-diastolic pressure and LV relaxation constant. Moreover, chronic omega-3 decreases LV systolic and diastolic diameters, LV weight and collagen density. Acute and chronic omega-3 increase LV γ-glutamyl-cysteine synthetase and oppose glutathione deficiency resulting in a reduction of myocardial oxidized glutathione. In experimental CHF, long-term omega-3 supplementation improves LV hemodynamics and function and prevents LV remodelling and glutathione deficiency. The latter might be one of the mechanisms involved, but whether other mechanism, independent of myocardial redox 'status', such as reduced inflammation, are implicated remains to be confirmed.


Asunto(s)
Ácidos Grasos Omega-3/farmacología , Glutatión/deficiencia , Glutatión/metabolismo , Insuficiencia Cardíaca/tratamiento farmacológico , Insuficiencia Cardíaca/metabolismo , Remodelación Ventricular/efectos de los fármacos , Animales , Presión Sanguínea/efectos de los fármacos , Gasto Cardíaco/efectos de los fármacos , Vasos Coronarios/efectos de los fármacos , Suplementos Dietéticos , Eritrocitos/metabolismo , Ácidos Grasos Omega-3/sangre , Glutamato-Cisteína Ligasa/metabolismo , Corazón/efectos de los fármacos , Insuficiencia Cardíaca/patología , Hemodinámica/efectos de los fármacos , Hígado/metabolismo , Masculino , Miocardio/metabolismo , Estrés Oxidativo/efectos de los fármacos , Ratas , Ratas Wistar , Resistencia Vascular/efectos de los fármacos , Función Ventricular Izquierda/efectos de los fármacos
2.
Free Radic Biol Med ; 49(5): 748-56, 2010 Sep 01.
Artículo en Inglés | MEDLINE | ID: mdl-20566328

RESUMEN

The goal of this study was to assess mitochondrial function and ROS production in an experimental model of cocaine-induced cardiac dysfunction. We hypothesized that cocaine abuse may lead to altered mitochondrial function that in turn may cause left ventricular dysfunction. Seven days of cocaine administration to rats led to an increased oxygen consumption detected in cardiac fibers, specifically through complex I and complex III. ROS levels were increased, specifically in interfibrillar mitochondria. In parallel there was a decrease in ATP synthesis, whereas no difference was observed in subsarcolemmal mitochondria. This uncoupling effect on oxidative phosphorylation was not detectable after short-term exposure to cocaine, suggesting that these mitochondrial abnormalities were a late rather than a primary event in the pathological response to cocaine. MitoQ, a mitochondrial-targeted antioxidant, was shown to completely prevent these mitochondrial abnormalities as well as cardiac dysfunction characterized here by a diastolic dysfunction studied with a conductance catheter to obtain pressure-volume data. Taken together, these results extend previous studies and demonstrate that cocaine-induced cardiac dysfunction may be due to a mitochondrial defect.


Asunto(s)
Cardiopatías/etiología , Cardiopatías/prevención & control , Enfermedades Mitocondriales/complicaciones , Compuestos Organofosforados/uso terapéutico , Ubiquinona/análogos & derivados , Animales , Antioxidantes/uso terapéutico , Cocaína , Trastornos Relacionados con Cocaína/etiología , Trastornos Relacionados con Cocaína/metabolismo , Trastornos Relacionados con Cocaína/prevención & control , Susceptibilidad a Enfermedades , Evaluación Preclínica de Medicamentos , Cardiopatías/inducido químicamente , Cardiopatías/metabolismo , Masculino , Mitocondrias Cardíacas/efectos de los fármacos , Mitocondrias Cardíacas/metabolismo , Mitocondrias Cardíacas/patología , Enfermedades Mitocondriales/metabolismo , Terapia Molecular Dirigida , Compuestos Organofosforados/farmacología , Consumo de Oxígeno/fisiología , Ratas , Ratas Wistar , Especies Reactivas de Oxígeno/metabolismo , Ubiquinona/farmacología , Ubiquinona/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA